Search Results - "Randeria, Hetal S."

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor by Gomez, Eliana B., Ebata, Kevin, Randeria, Hetal S., Rosendahl, Mary S., Cedervall, E. Peder, Morales, Tony H., Hanson, Lauren M., Brown, Nicholas E., Gong, Xueqian, Stephens, Jennifer, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A., Abada, Paolo B., Ballard, Joshua A., Allerston, Charles K., Brandhuber, Barbara J.

“…•Pirtobrutinib is a potent, noncovalent (reversible), highly selective inhibitor of BTK and C481-mutant BTK.•Pirtobrutinib is efficacious in B-cell models…”
Get full text

Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor by Gomez, Eliana B, Ebata, Kevin, Randeria, Hetal S, Rosendahl, Mary S, Cedervall, Ernst Peder, Morales, Tony H, Hanson, Lauren M, Brown, Nicholas E, Gong, Xueqian, Stephens, Jennifer Rachelle, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A, Abada, Paolo B, Ballard, Joshua A, Allerston, Charles K, Brandhuber, Barbara J

“…Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell driven malignancies. However, approved covalent BTK…”
Get full text

Abstract 2780: Unique pharmacodynamic properties conferred by differential binding to BTK, pirtobrutinib vs covalent inhibitors by Ballard, Joshua A., Ebata, Kevin, Randeria, Hetal S., Tinline, Garrett, Lee, Thomas, Hanson, Lauren M., Latham, John A., Cedervall, E. Peder, Chong, Jenny, Valle, Kyle B. Del, Collins, Bernard C., Morales, Tony H., Benedict, Thomas C., Schureck, Marc A., Bender, Ethan T., Mendoza, Christopher, Molina, David, Nakamoto, Meagan, Shiah, Hsiao-Chiao, Xu, Hao, Espada, Alfonso, Cano, Leticia, Allerston, Charles K., Schnier, Paul, Brandhuber, Barbara J.

“…Covalent Bruton tyrosine kinase inhibitors (cBTKi) have transformed the treatment of B cell malignancies. Despite the efficacy of cBTKi, treatment failure…”
Get full text